The abstract is read at the publisher; the summary is JClub's.
Once-weekly tirzepatide plus healthy lifestyle intervention in adolescents aged 12 to <18 with obesity or overweight and complications reduced BMI by 18.5% at week 72 versus 0.5% with placebo.
- Why it matters: Evidence for tirzepatide’s efficacy and safety in adolescents with obesity is limited, despite its adult approval and the need for effective weight-management options in younger patients.
- What they did: In a 72-week phase 3 randomized, double-blind trial across 31 centers in Canada, the Czech Republic, Israel, Italy, Poland, and the US, 160 adolescents were assigned 2:1 to tirzepatide (5, 10, or 15 mg) or placebo, both with lifestyle intervention.
- The result: Tirzepatide showed superiority for percent change in BMI (estimated treatment difference, -19.0 [95% CI, -23.9 to -14.1] percentage points; P < .001) and increased BMI-loss responses, with 79.6% achieving at least 5% reduction versus 28.5% on placebo; gastrointestinal events were most common.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.